Omega-3-6-9 fatty acids are important nutrients for all systems of the body to function normally, including skin, respiratory system, circulatory system, brain and organs. They are also known to reduce inflammation, which is the source of many illnesses including arthritis, stroke and heart disease. Although indispensable nutrients for good health, the human body cannot produce omega 3 and omega 6 fatty acids on its own, making omega-dense foods a critical component of a healthy diet.
Global consumer trends are increasingly moving toward healthier, more environmentally sustainable food choices such as plant-based ingredients. Millennials, a consumer segment with a growing position in the marketplace, are demanding alternatives to meat consumption as a source of protein.
These two drivers are creating significant opportunities for hemp, a plant-based protein source that is also rich in omega fatty acids.
Plant-based protein market driven by Millennials and socially conscious consumers
The global plant-based protein market In 2017 was valued at US$10.5 billion and is projected to grow at a rate of CAGR 5.7 percent to reach a value of US$16.3 billion by the end of 2025. The market applications for plant based proteins are numerous and wide-ranging, including supplements, nutritional powders, beverages, protein and nutritional bars, bakery and snacks, breakfast cereals, meat products, dairy and dairy alternative products, infant nutrition, pet food and treats and animal feed.
A major driver of this growth is the changing attitudes of consumers as they become better educated about the benefits of plant based nutrition and the environmental impact of meat-based protein consumption. Socially conscious consumers, according to market research, makes up about two-thirds of the market and their number one concern is environmental sustainability. Research firm Nielsen reported that in a recent consumer survey, 46 percent of respondents said they are willing to pay a premium for products and services that demonstrate a commitment to such concerns.
This INNspired Article is brought to you by:Naturally Splendid (TSXV:NSP)Â is the only publicly-traded company in the world offering investors an opportunity to gain exposure to the hemp-based healthy foods and omega markets.Send me an Investor Kit
A large majority of socially conscious consumers are under 40. In fact, millennials are considered one of the most powerful consumer groups in the North America, outspending baby boomers, and more than 60 percent consume plant-based meat alternatives.
According to a research study by Mintel, around 35 percent of Americans are eating more protein from sources other than red meat. In fact, per capita red meat and dairy consumption in the US have both fallen by one-third since the 1970s as consumers look to avoid cholesterol, saturated fat and the overuse of antibiotics and hormones contained in meat and dairy—all of which can have deleterious effects on one’s health.
“With so many consumers turning to protein from sources other than meat and poultry, there is an opportunity for marketers to reach a sizable group with concerns related to health, particularly cholesterol and fat content,” said Billy Roberts, senior food and drink analyst at Mintel.
In a significant strategic paradigm shift, Cargill the world’s largest privately held food and agriculture company, recently sold off the last of their US animal feedlots and its Swiss-based animal feed business in order to invest further in plant-based proteins. Last year, the corporate giant dropped the word “animal” from its protein division, opening the door to alternatives to meat-based proteins and have focused more on plant-based proteins.
Hemp leads the pack in plant-based proteins
The protein profile for hemp seed makes it a great alternative to meat and fish. Containing 33 grams of protein per 100 grams, hemp seeds are on par with or higher than most fish and meats and have more digestible protein than all other plant sources including soy, pea chia and flax. Considered a complete protein, hemp seed contains all the essential amino acids required for the human body for optimum health. Hemp contains 30 percent albumin (similar to egg white protein) and 65 percent globulin Edestin protein—an essential protein in cellular repair at the DNA level. In addition, Edestin is compatible with the human digestive system making it an easily digestible protein that doesn’t cause the same stomach issues as other forms of protein, including soy and whey.
Hemp also contains important minerals such as iron, magnesium, folate, copper, manganese in addition to insoluble fiber. And unlike flax and chia, hemp seeds are far more versatile and easy to incorporate into your daily diet as you don’t need to grind the seeds or soak them in water to obtain their nutritional benefits.
Plant-based diets are not only healthier than meat-based, they are also better for the environment—an important factor that appeals to today’s more socially conscious consumer. Global research firm Nielsen reports that in a recent study of consumer preferences, 46 percent of respondents said they would be willing to pay a premium for products and services from companies that take seriously their environmental and social impact.
Livestock production requires vast amounts of water, is a significant contributor to greenhouse gas emissions and responsible for deforestation in some regions. Agricultural production of plant-based foods, such as a vegan-based protein source like hemp seed, has a lower direct environmental impact than does the production of livestock, especially when it comes to water consumption, water and air pollution, and deforestation. Hemp is well suited to organic cultivation, requiring little if any use of pesticides, herbicides or petrochemical fertilizers.
The right Omega ratio is crucial
North American’s are not consuming enough omega 3s and that has a lot to do with our meat-based diets. Poor memory, fatigue, and depression may be signs of an omega deficiency.
Omega 3s are critically important to the body’s production of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)– both essential for human health. And the right balance between omega 3 and omega 6 is important to the body’s ability to convert omega 3 to DHA and EPA. Too much omega 6—commonly found in red meat, poultry and eggs—can actually inhibit this process and cause inflammation.
“A healthy diet should consist of roughly two to four times more omega-6 fatty acids than omega-3 fatty acids,” states a report by the University of Colorado, Colorado Springs. “A typical North American diet may contain 11 to 30 times more omega-6 fatty acids than omega-3 fatty acids, contributing to the rising rate of inflammatory disorders in the United States.”
Robust growth in the omega market
Consumers across North America, Europe and Asia are becoming more health conscious and adopting healthier lifestyles. This increasingly global trend is fueling significant market growth in dietary, nutraceutical and cosmetic applications for omega 3s. In 2016, the global market for functional food market reached US$250 billion while the omega-3 foods market reached US$37 billion.
Omega 3 supplements are a leading category within the nutraceutical industry. Grand View Research analysts expect by 2025 the omega 3 supplements market will hit $57.07 billion on significant growth in product applications. “Numerous factors such as urbanization and government efforts to educate consumers and provide superior healthcare services are likely to fuel the utilization of omega 3 based products,” stated a recent report by the firm. “In addition, increased consumer willingness to spend is anticipated to provide a positive outlook to the omega 3 supplements market.”
Outside of supplements, the applications for omega 3s are numerous and of great consequence to overall health. Omega products are gaining traction in the functional food market in categories that include dairy, pizza dough, pasta, baked goods, beverages and even pet food.
Omega 3 fatty acids promote the healthy development of the eyes, brain and nervous system. The Grand View Research report cites infant formula and the sports nutrition applications as significant contributors to future growth in the omega-3 market. In addition to the food industry, omegas are also used in cosmetics.
Hemp offers healthier, sustainable alternative to traditional marine sources
Fish is the most commonly consumed omega-rich food. The American Heart Association recommends including 2 servings of fish to your weekly menu; however rising levels of toxins such as mercury, dioxin and PCBs in many of the world’s fish supplies pose potential health risks. Even fish oil supplements may contain mercury, and farm-raised fish have significantly less omega 3s. Environmentally, there is increasingly consumer concern about sourcing omegas from farmed fish as well as from already rapidly declining global fish stocks .
While the fish oil sector is still expected to account for a large portion of the market, plant-based omega products such as those derived from hemp are beginning to play a larger role in the market as consumers push for more sustainable, healthier alternatives.
Seeds and nuts—whole, ground or as an oil— are the best plant-food sources of omega fatty acids. Plant-based sources such as hemp, flax and chia offer a healthier alternative to fish-based omega consumption. A further plus, incorporating more plant-based foods into your diet can help ensure a better balance of omega 3 and omega 6 in your diet.
Hemp seeds, for example, are comprised of nearly 85 percent EFAs and a one tablespoon of hemp seed oil provides more than the FDA’s daily EFA requirement. Hemp seed oil also has an ideal omega 3 to omega 6 ratio of approximately 1:3.
Fish oil’s inherent chemistry leads it to degrade faster than plant-based oils, increasing the potential for ingesting rancid pills. This risk is significantly reduced in hemp-derived omega supplements which have a much longer shelf-life. Omegas from fish have had limited success in fortifying foods. The fishy aftertaste associated with this type of fortification has had its challenges resulting in limited product development. Hemp can be more easily incorporated into an almost endless number products for omega fortification.
Hemp market growth
Hemp’s stellar nutritional value and impressive omega and protein profile have positioned it for market growth in a variety of industries. In the United States alone, hemp products—including shelled seed, protein powder, soaps and lotions, and CBD (cannabidiol) products— sold for an estimated total retail value of $688 million, according to Hemp Business Journal.
“The omega and protein markets are witnessing a monumental shift and hemp-derived omegas and proteins are becoming a driving factor. Increasing global awareness, education and continuous progress made amongst multiple countries in the EU, Asia and across North America and most recently in Australia have continued to open up new opportunities for hemp,” said Bryan Carson, Executive Vice President of Innovation at Naturally Splendid (TSXV:NSP). “With the continued lifting of prohibitions globally, new hemp research is now available to educate consumers on the nutritional benefits the plant provides. With regulations continuing to evolve in a positive fashion, these opportunities are expected to increase significantly.”
Through the application of advanced science and technology Naturally Splendid has built an award-winning portfolio of high quality hemp and plant-based extraction and formulation technologies and products. Distributed through North America, Asia and Europe and Australia, the company’s retail product lines span a number of market segments including functional foods, pet care and cosmetics, including its innovative omega ingredient HempOmega®.
In October 2017, Naturally Splendid received a provisional US patent for the market’s first hemp protein isolate superior in concentration to currently available hemp proteins. The ability to increase bioavailability and increase concentrations gives Naturally Splendid a unique advantage over most other hemp based companies who produce products primarily with the more standard hemp protein and omega as ingredients.
“Hemp offers its entire make-up to the food, beverage, pet, cosmetic and even bio-fuel industries,” explains Carson. “The revenue silos can be drawn to formulation of the plants naturally expressed oils (plant-based omega nutrition) derived from the plant.”
Growth categories for hemp products include cereals, sports nutrition and snacks, says Innova Market Insights, which reported a 76 percent jump in the bakery category for hemp applications between 2015 and 2016. And now with evolving new regulations allowing for more uses of the hemp plant such as CBD extraction and formulation, these opportunities are sure to expand.
The Canadian Government has proposed changes to existing industrial hemp regulations allowing for the extraction of CBD and its use in a wide variety of products. According to the recently released Canadian Government report, “A new pathway is proposed for NHP (Natural Health Product) submissions containing parts of the cannabis plant subject to the proposed Cannabis Act, such as products derived from cannabis flowers containing cannabinoids such as CBD. To minimize the risk of psychoactivity, the same 10 ppm THC limit would be applied to such products”. This extends to Veterinary Health Products, which are used to maintain or promote the health and welfare of animals.
Cosmetics and personal care is a growing market for hemp as consumers move toward more organic and CBD-based products. Grand View Research pegs the global market for organic personal care products at $10.6 billion. According to a report by CFN Media Group, “a recent review of available research suggested that cannabinoids could help reduce itching, modulate inflammation, and potentially treat certain skin cancers. Their anti-inflammatory and antioxidant characteristics could provide anti-aging properties, while hemp seed oil contains both omega-3 and omega-6 fatty acids to protect from sun damage.”
“CBD (a non-euphoric cannabinoid) is taking the market by storm and becoming accepted and deregulated across the globe and in Canada as well,” Carson added. “The research being conducted is proving up of the benefits of CBD and this is translating into a strong surge of demand from consumers seeking plant-based nutrition and relief from ailments and deficiencies.”
“We estimate that the hemp industry will grow to $1.8 billion in sales by 2020, led by hemp food, body care, and CBD-based products,” said Sean Murphy, Founder of Hemp Business Journal. “The data demonstrates that the hemp industry is growing quickly at 22% 5-year CAGR and being led by food and body care products.”
Further growth and opportunity
The health and wellness industry and all its subsets—including supplements, functional foods, and cosmetics—offer numerous entry points for investors to take advantage of the dynamic hemp-derived omega market. Consumer demand for more plant-based protein choices and the global awakening to the health benefits of cannabinoids will also serve as further drivers of growth for hemp-based businesses. The hemp sector is poised for significant growth in multiple consumer categories and the big differentiator as it often is in these emerging categories, will be product innovation of the inherent beneficial characteristics of hemp through solid research and development.
BevCanna Enterprises (CSE:BEV,OTCQQ:BVNNF,FWB:7BC) CEO Marcello Leone shared how the company is scaling up its products to forge partnerships and explore opportunities across Canada, the US and Western Europe.
“Getting your standard processing license and being fully compliant at a federal level is critical in Canada, and we were successful in getting that done. Now we’re getting ready to launch our Keef line of beverages within the next 45 days,” Leone said.
As a young company, Leone said BevCanna has only started, but it took a four-pronged approach to make sure that it is a revenue-generating company prepared for the opening of many jurisdictions for CBD-based products.
“We are blessed that we have a beautiful infrastructure of our own, a state-of-the-art bottling facility with a capacity of almost 200 million bottles per annum and a strong balance sheet of $55 million. We are in a strong position to scale and grow this company.”
BevCanna has received a Standard Processing License from Health Canada and is now fully authorized to begin production at its full-service, high-capacity beverage manufacturing facility. The company will begin production of its white-label products, number one US cannabis beverage brand Keef and its in-house beverages through licensed Canadian retailers, positioning the company to fully capitalize on the burgeoning Canadian cannabis-infused beverage sector.
Watch the full interview with CEO Marcello Leone above.
This interview is sponsored by BevCanna Enterprises (CSE:BEV,OTCQB:BVNNF,FWB:7BC). This interview provides information which was sourced by the Investing News Network (INN) and approved by BevCanna Enterprises in order to help investors learn more about the company. BevCanna Enterprises is a client of INN. The company’s campaign fees pay for INN to create and update this interview.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with BevCanna Enterprises and seek advice from a qualified investment advisor.
BioHarvest Sciences (CSE: BHSC) will be presenting at the Benzinga Cleantech Small Cap Conference taking place on April 22, 2021. We invite our shareholders and all interested parties to explore cleantech small cap investment opportunities through two days of networking, dealmaking and discovery.
Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/clean-tech/
About the Benzinga Cleantech Small Cap Conference
The Benzinga Cleantech Small Cap Conference bridges the gap between cleantech companies, investors, and traders. Discover the companies in the cleantech industry who are moving the world forward through accessible green energy, energy efficiency, and innovative sustainability solutions.
For more information and/or to register for the conference please visit: https://www.benzinga.com/events/small-cap/clean-tech/
We look forward to seeing you there.
News Provided by Newsfile via QuoteMedia
Positive distributor feedback and strong consumer interest accelerating launch with distributors
Emerging leader in innovative health and wellness beverages and products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that its wholly-owned subsidiary Naturo Group has successfully completed its initial shipment of TRACE plant-based products to one of Japan’s largest beverage distributors.
Following up on its recently announced Japanese distribution agreement with Mirai Marketing Inc., the Company is now in active discussions with established beverage distributors to leverage their robust distribution networks and integrate TRACE’s proprietary plant-based mineral formulation into their distribution pipeline, targeting the growing health-conscious consumer segment in Japan.
“BevCanna’s market research on Japanese purchaser preferences confirms that these consumers are very responsive to natural, health-conscious products, and that TRACE’s proprietary plant-based mineralized beverages and nutraceuticals will be well received,” said Melise Panetta, President of BevCanna. “Our first product shipment to Japan will build our distribution network within this burgeoning market and solidify Japan as a primary market within our international expansion strategy.”
About BevCanna Enterprises Inc.
BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) is a diversified health & wellness beverage and natural products company. BevCanna develops and manufactures a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients.
With decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale, the team demonstrates an expertise unmatched in the nutraceutical and cannabis-infused beverage categories. Based in British Columbia, Canada, BevCanna owns a pristine alkaline spring water aquifer and a world–class 40,000–square–foot, HACCP certified manufacturing facility, with a bottling capacity of up to 210M bottles annually. BevCanna’s extensive distribution network includes more than 3,000 points of retail distribution through its market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with #1 U.S. cannabis beverage company Keef Brands .
Disclaimer for Forward-Looking Information
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding: that the Company is now in active discussions with established beverage distributors to leverage their robust distribution networks and integrate TRACE’s proprietary plant-based mineral formulation into their distribution pipeline, targeting the growing health-conscious consumer segment in Japan; the Company’s first product shipment to Japan will build its distribution network within this burgeoning market and solidify Japan as a primary market within its international expansion strategy; and other statements regarding the business plans of the Company. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements.
Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include, among other things: general market conditions; changes to consumer preferences; volatility of commodity prices; future legislative, tax and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the inability to implement business strategies; competition; currency and interest rate fluctuations; inability to successfully negotiate and enter into commercial arrangements with other parties; and other factors beyond the control of the Company and its commercial partners. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.
On behalf of the Board of Directors:
John Campbell, Chief Financial Officer and Chief Strategy Officer
Director, BevCanna Enterprises Inc.
For media enquiries or interviews, please contact:
Wynn Theriault, Thirty Dash Communications Inc.
News Provided by Business Wire via QuoteMedia
Cresco Labs Announces the Appointment of Tarik Brooks to Its Board of Directors and the Retirement of Dominic Sergi
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced an additional refreshment of its board of directors to further strengthen its leadership in the cannabis industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005351/en/
Cresco Labs appoints Tarik Brooks, President of Combs Enterprises, to its Board of Directors (Photo: Business Wire)
Appointment of Tarik Brooks
Cresco Labs has appointed Tarik Brooks to its board of directors, effective immediately. Mr. Brooks is a seasoned executive with more than 22 years of experience driving large scale business transformations across several industries including spirits, hospitality and media.
Currently, as President of Combs Enterprises, Mr. Brooks oversees all business operations and investments owned by Sean “Diddy” Combs. This diverse portfolio includes ventures in spirits (Ciroc Vodka and DeLeon Tequila), media (Revolt TV), music (Bad Boy Records), consumer packaged goods (AquaHydrate), and education (Capital Preparatory Schools). Mr. Brooks also leads all new business development activity, including the launch of “Our Fair Share”, a platform to help minority owned businesses access capital through the Paycheck Protection Program (PPP).
Prior to his current role, Mr. Brooks was the Chief Operating Officer of Account Management and Trading at Bridgewater Associates, the world’s largest hedge fund. Earlier in his career, Mr. Brooks served as Executive Vice President at RLJ Companies, a portfolio of companies owned by investor Robert L. Johnson, where Mr. Brooks led the development of gaming/nightlife ventures in the Caribbean and the completion of RLJ Kendeja, a resort hotel in Liberia.
Throughout his career, Brooks has negotiated transactions, including acquisitions and capital raises, led major strategic initiatives, and oversaw compliance in highly regulated industries. Mr. Brooks is a graduate of Howard University and Harvard Business School.
“I’m thrilled to welcome Tarik Brooks to our board of directors. He has remarkable experience building and managing consumer brands and will be an invaluable member of our organization as cannabis continues to evolve as a consumer packaged good,” said Tom Manning, Cresco Labs Executive Chairman. “We’ve taken a measured approach to building our board, periodically making refreshments that add new skills and experience to the group. Tarik represents another key appointment for Cresco Labs at a critical time of growth and expansion for the company.”
Retirement of Dominic Sergi
The Company announced today that Dominic Sergi, an original founder of Cresco Labs, has retired from the Company’s board of directors as part of the planned board refreshment process. Mr. Sergi currently serves as CEO of Clear Height Properties and spends his free time supporting the Nicholas D. Sergi Foundation. Mr. Sergi has been a foundational part of Cresco Labs since the company’s inception and his experience in real estate development has played an instrumental part in the construction of Cresco Labs’ asset base.
“I want to sincerely thank Dominic for his many years of service and for helping to guide this organization toward the top of the cannabis industry. Dominic is one of the most considerate and giving people I know and it has been a pleasure building this Company together,” said Charlie Bachtell, CEO of Cresco Labs.
About Cresco Labs Inc.
Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy’s Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com .
Forward Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms and includes, but is not limited to, statements relating to the expected timing by which Bluma Wellness will be de-listed from the CSE and the intention to apply to have Bluma Wellness cease to be a reporting issuer and terminate its public reporting obligations. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2020 dated March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.
Jason Erkes, Cresco Labs
Chief Communications Officer
Jake Graves, Cresco Labs
Manager, Investor Relations
For general Cresco Labs inquiries:
News Provided by Business Wire via QuoteMedia
– Study to examine DehydraTECH TM CBD’s ability to control blood pressure
– First of three human clinical studies hoped to validate Lexaria’s patented technology for hypertension relief
Kelowna, British Columbia, April 22, 2021 Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that its human clinical hypertension study HYPER-H21-1 is officially underway. Lexaria’s patented DehydraTECH CBD formulation will be examined to assess its ability to control blood pressure and assess impact on inflammation.
“We are very pleased that dosing of human volunteers as part of Lexaria’s hypertension study has begun,” said Lexaria CEO Mr. Chris Bunka. “Dosing is expected to be completed, on schedule, within several weeks, and we may be in a position to report preliminary data in July or thereabouts. Despite challenges in launching a human clinical study during a global pandemic, Lexaria’s Europe-based research partners have done an excellent job of balancing the need for scientific validation for a potential new hypertension treatment, with the required safety protocols currently in place.”
HYPER-H21-1 is a randomized, double-blinded, controlled human clinical study expected to involve 24 human volunteers with symptoms of either pre-hypertension, or mild hypertension. A single 300mg dose of an advanced DehydraTECH TM 2.0 CBD formulation will be evaluated relative to a concentration-matched control without Lexaria’s DehydraTECH enhancements.
Time series blood pressure and heart rate analyses are the primary objectives of this study. Secondary objectives include speed and rate of absorption of the CBD and its main metabolites (pharmacokinetics or “PK” assessments), as well as evaluation of inflammatory markers associated with cardiovascular disease and gold-standard biomarkers of nitric oxide. This latter measure provides mechanistic insight into the anticipated reduction in blood pressure via vasodilation.
These i nflammatory marker assessments may also be applicable to Lexaria’s research initiatives in the antiviral therapeutics space whereby effective anti-inflammatory therapies are also useful in treating diseases like COVID-19 or other common pro-inflammatory conditions.
Since a large array of data points will be generated and analyzed, final reporting on this study is likely to be reported in early September.
There are five studies in Lexaria’s 2021 hypertension program which are expected to generate data required to further support the validity of using DehydraTECH-processed CBD as a potential hypertension treatment across various applications. Lexaria has received 18 granted patents internationally, including issuances in the European Union and Australia specifically to use DehydraTECH-processed CBD to treat heart disease.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com .
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Copyright (c) 2021 TheNewswire – All rights reserved.
News Provided by TheNewsWire via QuoteMedia